Medicine and Dentistry
Patient
100%
Multiple Sclerosis
71%
COVID-19
44%
Therapeutic Procedure
35%
Combination Therapy
31%
Myositis
20%
Muscle
20%
Infection
19%
Magnetic Resonance Imaging
18%
Symptom
18%
Diseases
16%
Follow up
14%
Association
13%
Inpatient
13%
Severe Acute Respiratory Syndrome Coronavirus 2
13%
Alemtuzumab
13%
Onset Age
12%
Diagnosis
12%
Analysis
12%
Complication
11%
Cells
11%
Odds Ratio
10%
Lesion
10%
CD20
9%
Prevalence
9%
Autoimmunity
9%
Case Report
8%
Lymphocytopenia
8%
Neurologic Disease
8%
Ocrelizumab
8%
Methylprednisolone
8%
Drug
8%
Chemotherapeutic Agent
8%
Outpatient
8%
Antibody
8%
Fumaric Acid Dimethyl Ester
7%
Liver Injury
7%
Oculopharyngeal Muscular Dystrophy
7%
Valerian
7%
Cyclophosphamide
7%
Ixekizumab
7%
Epidermal Growth Factor Receptor
7%
Demyelination
7%
Thyroid Gland
7%
Upper Limb
7%
Haplotype
7%
Recurrent Disease
6%
Surgery
6%
Muscle Biopsy
6%
Serological Test
6%
Neuroscience
Multiple Sclerosis
93%
Long Non-Coding RNA
19%
Relapsing Remitting Multiple Sclerosis
16%
Amyotrophic Lateral Sclerosis
15%
Transverse Myelitis
15%
Ocrelizumab
15%
Magnetic Resonance Imaging
14%
Fingolimod
14%
Myelitis
14%
Antibodies
13%
Differential Diagnosis
12%
Phenotype
12%
Chitinase
11%
Muscle Disorder
11%
Magnetic Resonance Imaging
11%
Myelin Basic Protein
10%
Sarcoidosis
10%
Osteopontin
9%
MicroRNA
8%
Natalizumab
8%
Rituximab
8%
Cladribine
8%
Untranslated Region
8%
Teriflunomide
8%
Acute Disseminated Encephalomyelitis
7%
Alpha Blocker
7%
Tumor Necrosis Factor Alpha
7%
Ixekizumab
7%
Coronavirus
7%
Methylation
7%
Myositis
7%
Circulating microRNA
7%
HLA-DRB1
7%
Haplotype
7%
Gene
6%
Promoter Region
6%
Interferon
6%
Expanded Disability Status Scale
5%
Lymph Node
5%
Computed Tomography
5%
Treatment of Multiple Sclerosis
5%
Immunology and Microbiology
Multiple Sclerosis
71%
Ocrelizumab
20%
COVID-19
20%
Liquid
16%
Muscle
14%
Monospecific Antibody
13%
Cells
13%
Electric Potential
12%
Phenotype
12%
Osteopontin
11%
Vaccine Efficacy
10%
Time
9%
CD20
8%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Regulatory T Cell
8%
Inclusion Body Myositis
8%
Modulation
8%
Fingolimod
7%
Fumaric Acid Dimethyl Ester
7%
CD44
7%
Autoimmune Disease
7%
Tumor Necrosis Factor Alpha
7%
CD4
7%
Humoral Immunity
7%
Macrophage
7%
Haplotype
7%
B Cell Activating Factor
6%
Rituximab
6%
Natalizumab
6%
Lymphopenia
6%
Immunity
5%
Prevalence
5%
CXCL13
5%
CHI3L1
5%
Myelin
5%
Association
5%
TLR2
5%
T Helper Cell
5%
Dynamics
5%
Lymphocyte Subpopulation
5%
Age
5%
